A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma
Clinical trial NCT04834973 · TERMINATED
Trial details
- NCT number
- NCT04834973
- Sponsor
- QBiotics Group Limited
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-07
- Primary completion
- 2022-07-12
- Enrollment
- 3
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.